American Diabetes Association. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl 1):S20–S42. https://doi.org/10.2337/dc24-S002

K.L. Ong, L.K. Stafford, S.A. McLaughlin, E.J. Boyko, S.E. Vollset, A.E. Smith et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023)

Article  Google Scholar 

M.J. Fowler. Microvascular and macrovascular complications of diabetes [Internet]. Clin. Diabetes•. 2008. Available from: http://clinical.diabetesjournals.org

M.R. Schuyler, D.E. Niewoehner, S.R. Inkley, R. Kohn. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev. Respir. Dis. 113, 37-41 (1976).

S.A. Paschou, E. Bletsa, K. Saltiki, P. Kazakou, K. Kantreva, P. Katsaounou. et al. Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes. Nutrients. 14, 4989 (2022)

S.F. Ehrlich, C.P. Quesenberry, S.K. Van Den Eeden, J. Shan, A. Ferrara, Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 33, 55–60 (2010)

Article  PubMed  Google Scholar 

T. Enomoto, J. Usuki, A. Azuma, T. Nakagawa, S. Kudoh, Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 123, 2007–2011 (2003)

Article  PubMed  Google Scholar 

Wang D., Ma Y., Tong X., Zhang Y., Fan H. Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis. Front. Public Health. 8, 196 (20200).

C. Hyldgaard, O. Hilberg, E. Bendstrup, How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir. Med. 108, 647–653 (2014)

Article  PubMed  Google Scholar 

J.B. Kornum, R.W. Thomsen, A. Riis, H.H. Lervang, H.C. Schønheyder, H.T. Sørensen, Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31, 1541–1545 (2008)

Article  PubMed  PubMed Central  Google Scholar 

A. Al-Sayyar, K.D. Hulme, R. Thibaut, J. Bayry, F.J. Sheedy, K.R. Short. et al. Respiratory tract infections in diabetes – lessons from tuberculosis and influenza to guide understanding of COVID-19 severity. Front. Endocrinol. 13, 91923 (2022).

S.J. McGurnaghan, A. Weir, J. Bishop, S. Kennedy, L.A.K. Blackbourn, D.A. McAllister et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 9, 82–93 (2021)

Article  CAS  PubMed  Google Scholar 

H. Zheng, J. Wu, Z. Jin, L.J. Yan. Potential biochemical mechanisms of lung injury in diabetes. Aging Dis. 8, 7 (2017).

S. Singh, Y.S. Prakash, A. Linneberg, A. Agrawal, Insulin and the lung: connecting asthma and metabolic syndrome. J. Allergy 2013, 1–8 (2013)

Article  Google Scholar 

L. Zhang, f. Jiang, Y. Xie, Y. Mo, X. Zhang, C. Liu. Diabetic endothelial microangiopathy and pulmonary dysfunction. Front. Endocrinol. 14, 1073878 (2023).

L. Fuso, D. Pitocco, A. Longobardi, F. Zaccardi, C. Contu, C. Pozzuto et al. Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 28, 370–375 (2012)

Article  PubMed  Google Scholar 

S.A. Meo. Significance of spirometry in diabetic patients. Int. J. Diabetes Mellit. 2, 47–50 (2010).

A. Aparna. Pulmonary function tests in type 2 diabetics and non-diabetic people - A comparative study. J. Clin. Diagnos. Res. 7, 1606–1608 (2013)

CAS  Google Scholar 

S. Mittal, M. Mittal, M. Jindal, S. Srivastava, S. Sinha. Evaluation of pulmonary functions in patients with type 2 diabetes mellitus: a cross-sectional study. Cureus 15, 3–4 (2023).

Google Scholar 

O.L. Klein, J.A. Krishnan, S. Glick, L.J. Smith. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic Med. 27, 977–987 (2010).

W. Jiao. 1 AIC, LMG-MMER, LX. Causal associations of sleep apnea and snoring with type 2 diabetes and glycemic traits and the role of BMI. Obesity. 31, 652−664 (2023)

S. Momtazmanesh, S.S. Moghaddam, S.-H. Ghamari, E.M. Rad, N. Rezaei, P. Shobeiri et al. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine [Internet] 59, 101936 (2023). https://linkinghub.elsevier.com/retrieve/pii/S258953702300113X

Article  Google Scholar 

N. Salam, M. Jevtic, S. Safiri, M. Abdollahi. Global burden of lower respiratory infections during the last three decades [Internet]. Available from: https://vizhub.healthdata.org/gbd-compare/

R. Nevola, R. Epifani, S. Imbriani, G. Tortorella, C. Aprea, R. Galiero et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int. J. Mol. Sci. 24, 1703 (2023)

E.D. Michos, G.L. Bakris, H.W. Rodbard, K.R. Tuttle. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am. J. Prev. Cardiol. 14, 10052 (2023)

M. Grieco, A. Giorgi, M.C. Gentile, M. d’Erme, S. Morano, B. Maras et al. Glucagon-Like Peptide-1: a focus on neurodegenerative diseases. Front. Neurosci. 13, 1112 (2019)

H. Yaribeygi, M. Maleki, T. Jamialahmadi, S.A. Moallem, A. Sahebkar. Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI J. 22, 403–414 (2023)

A. Pawlos, M. Broncel, E. Woźniak, P. Gorzelak-Pabiś. Neuroprotective effect of SGLT2 inhibitors. Molecules. 23, 7213 2021.

J. Nespoux, V. Vallon. Renal effects of SGLT2 inhibitors: an update. Curr. Opin. Nephrol. Hypertens. 29, 190–198 (2020)

W. Widiarti, A.C. Sukmajaya, D. Nugraha, F.F. Alkaff. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. 15, 837–843 (2021)

C. de Graaf, D. Donnelly, D. Wootten, J. Lau, P.M. Sexton, L.J. Miller et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev 68, 954–1013 (2016)

Article  PubMed  PubMed Central  Google Scholar 

M. Körner, M. Stöckli, B. Waser, J.C. Reubi, GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nuclear Med. 48, 736–743 (2007)

Article  Google Scholar 

C.O. Mendivil, H. Koziel, J.D. Brain. Metabolic hormones, apolipoproteins, adipokines, and cytokines in the alveolar lining fluid of healthy adults: compartmentalization and physiological correlates. PLoS ONE. 10, e0123344 (2015)

D.V. Nguyen, A. Linderholm, A. Haczku, N. Kenyon. Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma. Pharmacol. Ther.180, 139–143 (2017).

A.D. Altintas Dogan, O. Hilberg, S. Hess, T.T. Jensen, E.M. Bladbjerg, C.B. Juhl, Respiratory effects of treatment with a glucagon-like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int. J. COPD 17, 405–414 (2022)

Article  CAS  Google Scholar 

R. Pradhan, S. Lu, H. Yin, O.H.Y. Yu, P. Ernst, S. Suissa et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: Population based cohort study. BMJ 379, 8–10 (2022)

Google Scholar 

Y. Albogami, K. Cusi, M.J. Daniels, Y.J.J. Wei, A.G. Winterstein, Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care 44, 1344–1352 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Rogliani, M.G. Matera, L. Calzetta, N.A. Hanania, C. Page, I. Rossi et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir. Med. 154, 86–92 (2019)

Article  PubMed  Google Scholar 

J.P. Wei, C.L. Yang, W.H. Leng, L.L. Ding, G.H. Zhao, Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs. Clin. Respir. J. 15, 847–850 (2021)

Article  CAS  PubMed  Google Scholar 

M. Yu, R. Wang, L. Pei, X. Zhang, J. Wei, Y. Wen et al. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol. Metab. Syndr. 15, 164 (2023).

A. Chaudhuri, H. Ghanim, M. Vora, C.L. Sia, K. Korzeniewski, S. Dhindsa et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198–207 (2012)

Article  CAS  PubMed  Google Scholar 

G. Bendotti, L. Montefusco, M.E. Lunati, V. Usuelli, I. Pastore, E. Lazzaroni et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol. Res. 182, 106320 (2022)

Article  CAS  PubMed  Google Scholar 

W. Zhou, W. Shao, Y. Zhang, D. Liu, M. Liu, T. Jin, Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein. Am. J. Physiol. Endocrinol. Metab. 319, E568–E578 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P.D. Mitchell, B.M. Salter, J.P. Oliveria, A. El-Gammal, D. Tworek, S.G. Smith et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin. Exp. Allergy 47, 331–338 (2017)

Article  CAS  PubMed  Google Scholar 

T. Zhu, X.L. Wu, W. Zhang, M. Xiao, Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice. Int. J. Mol. Sci. 16, 20195–20211 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Gou, T. Zhu, W. Wang, M. Xiao, X.C. Wang, Z.H. Chen, Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. Int. Immunopharmacol. 22, 498–504 (2014)

Article  PubMed  Google Scholar 

B. Baer, N.D. Putz, K. Riedmann, S. Gonski, J. Lin, L.B. Ware et al. Liraglutide pretreatment attenuates sepsis-induced acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol 325, L368–L384 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

W. Yue, F. Dang, X. Zang, Y. Du, X. Fan, H. Su, T. Pan. Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis. Eur J Pharmacol. 949, 175730 (2023)

E. Vara, J. Arias-Díaz, C. Garcia, L. Balibrea, E. Blázquez. Glucagon-like Peptide-1(7-36) Amide Stimulates Surfactant Secretion in Human Type II Pneumocytes [Internet]. Am. J. Respir. Crit. Care. Med. (2001). Available from: www.atsjournals.org

H.P. Haagsman, R.V. Diemel. Surfactant-associated proteins: functions and structural variation. Compar. Biochem. Physiol. Part A. 129, 91−108 (2001)

J. Fandiño, L. Toba, L.C. González-Matías, Y. Diz-Chaves, F. Mallo. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci. Rep. 10, 18091 (2020)

T. Zhu, Li C., X. Zhang, C. Ye, S. Tang, W. Zhang et al. GLP-1 analogue liraglutide enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway. Mediat. Inflamm. 2018, 3601454 (2018)

C. López-Cano, A. Ciudin, E. Sánchez, F.J. Tinahones, F. Barbé, M. Dalmases et al. Liraglutide improves forced vital capacity in individuals with Type 2 diabetes: data from the randomized crossover LIRALUNG Study. Diabetes. 71, 315–320 (2022)

Article  PubMed  Google Scholar 

N.E. Viby, M.S. Isidor, K.B. Buggeskov, S.S. Poulsen, J.B. Hansen, H. Kissow, Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 154, 4503–4511 (2013)

Article  CAS  PubMed  Google Scholar 

P. Rogliani, L. Calzetta, B. Capuani, F. Facciolo, M. Cazzola, D. Lauro et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 55